Gain Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine Months Ended September 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flow from operating activities: · · · · | ||||||
| Net loss | | $(13,444,711) | | $(15,623,518) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation and amortization | | 67,724 | | 65,805 | ||
| Stock-based compensation expense | | 1,345,207 | | 1,401,528 | ||
| Other non-cash items | | | 272,825 | | | 793,744 |
| | | | | | | |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | | 399,609 | | | (386,545) |
| Long term deposits and other noncurrent assets | | 10,895 | | 2,319 | ||
| Accounts payable and other current liabilities | | (1,030,579) | | 316,652 | ||
| Defined benefit pension plan | | | (86,862) | | | (103,702) |
| Deferred grant income | | 11,173 | | (313,228) | ||
| Total changes in operating assets and liabilities | | | (695,764) | | | (484,504) |
| Cash used in operating activities | | | (12,454,719) | | | (13,846,945) |
| | | | | | | |
| Cash flow from financing activities: | | | | | ||
| Net proceeds from issuance of shares in ATM offering (Note 13) | | 3,597,231 | | 4,910,240 | ||
| Net proceeds from issuance of shares and warrants in public offering (Note 13) | | — | | 7,411,554 | ||
| Net proceeds from the exercise of warrants (Note 13) | | | 2,063 | | | 41,745 |
| Payments of offering costs (Note 13) | | | — | | | (395,478) |
| Payments of current portion of long-term debt (Note 11) | | | (75,439) | | | (71,476) |
| Cash provided by financing activities | | | 3,523,855 | | | 11,896,585 |
| Effect of exchange rate changes | | | (211,045) | | | 376,272 |
| Net decrease in cash, cash equivalents and restricted cash | | | (9,141,909) | | | (1,574,088) |
| Cash, cash equivalents and restricted cash at beginning of period | | 20,873,924 | | 10,417,558 | ||
| Cash, cash equivalents and restricted cash at end of period | | $11,732,015 | | $8,843,470 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.